Biologix Hair Inc. Appoints Dr. Michael Stocker Director and CEO; J. Gregory Wilson Appointed CFO
5/15/2013 10:46:58 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Biologix Hair Inc. Appoints Dr. Michael Stocker Director and Chief Executive Officer; J. Gregory Wilson Appointed Chief Financial Officer
TORONTO, ONTARIO--(Marketwired - May 15, 2013) - Biologix Hair Inc. (BLGX) (BLGX) has appointed Dr. Michael Stocker as Chief Executive Officer and to the Company's Board of Directors and J. Gregory Wilson as Chief Financial Officer. Outgoing CEO, Ron Holland, will continue to serve as Chairman of the Board of Directors.
Biologix Chairman Ron Holland stated: "Over the past weeks and months, as we prepare to make application to obtain an NYSE Markets listing, we have significantly expanded the independence of our board of directors and recruited key personnel to round out our executive management team. With Dr. Stocker serving as CEO and Greg Wilson CFO, I am extremely confident that Biologix has a world-class operational team with internationally experienced leadership capable of fast-tracking the company's growth over the next several years."
Dr. Michael Stocker - Director, Chief Executive Officer
Michael Stocker, PhD, has held executive positions in several companies, mainly in Latin America. He was part of the FUNDES International management team as well as Regional Manager Latin America for PROPEL Colombia. He also worked for the Boston Consulting Group (BCG), in its offices in Mexico, Spain and Switzerland, in connection with the development of business strategies and management structure for several worldwide active corporations and companies, among them Fortune 500 companies.
The consulting and technology branch of his own company, the Stocker Group, has offices in five countries and offers Risk and Knowledge Management to international clients in several countries, including the United Nations and several governments in Latin America. In the mining industry, Dr. Stocker worked as an executive, consultant and advisor for several companies.
Dr. Stocker has initiated and invested in several ventures, among them a company he founded in 2010 (Medtechtrade.com) in the medical equipment sector, which is currently offering second-hand medical equipment from hospitals in Europe to hospitals on all continents in need of such equipment.
Dr. Stocker has previously been retained as an adviser and consultant by the Inter-American Development Bank, the United Nations Industrial Development Organization (UNIDO), the Swiss State Secretariat for Economic Affairs (SECO), the World Bank's International Finance Corporation (IFC) and the Organization of American States (OAS) as well as several private companies.
Dr. Stocker holds a PhD in Economics from the University of St. Gallen, Switzerland and an MBA from the Community of European Management Schools (CEMS). He has lived and worked in Latin America, chiefly in Chile, Colombia and Costa Rica, since 1993.
J. Gregory Wilson - Chief Financial Officer
J. Gregory Wilson is an entrepreneur and corporate finance strategist with more than 20 years experience advising and structuring capital market financings for start-up enterprises and assisting in developing and implementing successful business plans.
Upon graduation with a Bachelor's degree in Economics from Queen's University in Kingston, Ontario, Canada in 1985, Greg began his career as a marketing representative with IBM. In 1988, he started and operated a business in the wellness industry that ultimately employed a staff of over 200 and generated annual revenues in excess of $13 million. Greg sat on the National Advisory Board for this company in 1989 and 1990.
In 1992, Greg began a career in finance working with top Canadian investment firm Scotia McLeod. Over the ensuing 5 years, he went on to work with the Bank of Montreal's investment arm, Nesbitt Burns, before finishing his mainstream financial career with Merrill Lynch in 1997. In late 1997, Greg started EMT Capital Corp. and over the past 15 years has worked on a number of successful capital market transactions, including M&As, IPOs and private equity financings.
In 2005, Greg was part of the group that founded Paramount Gold & Silver Corp., a precious metals exploration company that currently trades on the NYSE and TSX. In early 2009, he co-founded and led the financing of a renewable energy company with a portfolio of over 600 megawatts of wind projects in Canada, the United States and Germany. He advised a client in late 2009 on the purchase of Consumer Choice Awards, a 23-year-old private company with operations across Canada. Greg negotiated and structured the acquisition with the seller and raised the equity component of the purchase price. Greg continues to sit on the Board of Directors.
Greg has completed the Canadian Investment Management (CIM) program and has been awarded the Fellow of the Canadian Securities Institute (FCSI) designation. He currently resides in Ottawa, Canada with his wife, Joanne, and their four children.
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
Biologix Hair Inc.
Toll Free: 1 855.292.8585